Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement

NCT01675440 · View on ClinicalTrials.gov ↗

Study Summary

To evaluate the safety and efficacy of the Medtronic CoreValve® System for the treatment of symptomatic severe aortic stenosis in subjects with significant comorbidities in whom the risk of surgical aortic valve replacement has a predicted operative mortality or serious, irreversible morbidity risk of ≥50% at 30 days.

Conditions Studied

Interventions

  • DEVICE Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Study Locations (20)

California

  • Kaiser Permanente - Los Angeles Medical Center — Los Angeles
  • University of Southern California University Hospital — Los Angeles
  • VA Palo Alto Health Care System — Palo Alto

Connecticut

  • Hartford Hospital — Hartford
  • Yale New Haven Hospital — New Haven

Florida

  • University of Miami Health System / Jackson Memorial Hospital — Miami
  • Mount Sinai Medical Center — Miami Beach

Georgia

  • Piedmont Heart Institute — Atlanta
  • Saint Joseph's Hospital of Atlanta — Atlanta

Michigan

  • University of Michigan Health Systems — Ann Arbor
  • Detroit Medical Center Cardiovascular Institute — Detroit

Arizona

  • Banner Good Samaritan — Phoenix

District of Columbia

  • Washington Hospital Center / Georgetown Hospital — Washington D.C.

Illinois

  • Loyola University Medical Center — Maywood

Trial Details

FieldValue
Enrollment Target 782 participants
Start Date 2012-08
Est. Completion 2026-01

Sponsor

Medtronic Cardiovascular

49 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01675440

The ClinicalTrials.gov registry entry for NCT01675440 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 782 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 49 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Severe Aortic Stenosis appearing as the primary indexed condition, and to 1 intervention — of which Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01675440 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, Connecticut, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01675440 about?

NCT01675440 is a clinical study titled "Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement". To evaluate the safety and efficacy of the Medtronic CoreValve® System for the treatment of symptomatic severe aortic stenosis in subjects with significant comorbidities in whom the risk of surgical aortic valve replacement has a predicted operative mortality or serious, irreversible morbidity risk ...

What is the current status of trial NCT01675440?

This trial is currently active not recruiting. The enrollment target is 782 participants. The study started on 2012-08. Estimated completion is 2026-01.

What conditions does trial NCT01675440 study?

This clinical trial studies the following conditions: Severe Aortic Stenosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01675440?

The interventions under investigation include: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01675440?

This trial is sponsored by Medtronic Cardiovascular, which has 49 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01675440 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial